Antibody-Based Therapies for the Treatment of Hodgkin Lymphoma in Older Patients
Mené sur 83 patients atteints d'un lymphome hodgkinien classique de stade avancé (âge médian : 67 ans), cet essai multicentrique de phase II évalue l'efficacité, du point de vue du taux de rémission complète, et la toxicité d'une chimiothérapie de première ligne de type BrECADD guidée par PET-scan (brentuximab védotin, étoposide, cyclophosphamide, doxorubicine, dacarbazine et dexaméthasone)
Although the age distribution varies between regions, 20%-25% of patients with classical Hodgkin lymphoma (cHL) are older than 60 years at the time of presentation.5 Whilst the results of treatment in younger patients have shown steady improvement over the past 5 decades, treatment of cHL in older adults has proven more of a challenge, with survival outcomes significantly less favorable and with less evidence of progress. Population-based comparisons show a more marked increment in overall mortality in those with cHL older than 60 years, with lymphoma leading the causes of death in this group.6 Multiple factors contribute to the poor prognosis for these patients, and there has long been an unmet need to improve outcomes.
Journal of Clinical Oncology , éditorial, 2025